- Home
- BWEN vs CUE Comparison
BWEN vs CUE Comparison
Compare BWEN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWEN
- CUE
- Stock Information
- Founded
- BWEN N/A
- CUE 2014
- Country
- BWEN United States
- CUE United States
- Employees
- BWEN N/A
- CUE N/A
- Industry
- BWEN Industrial Machinery/Components
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- BWEN Industrials
- CUE Health Care
- Exchange
- BWEN Nasdaq
- CUE Nasdaq
- Market Cap
- BWEN 43.0M
- CUE 48.0M
- IPO Year
- BWEN N/A
- CUE 2018
- Fundamental
- Price
- BWEN $1.88
- CUE $0.78
- Analyst Decision
- BWEN Strong Buy
- CUE Strong Buy
- Analyst Count
- BWEN 3
- CUE 3
- Target Price
- BWEN $4.50
- CUE $3.00
- AVG Volume (30 Days)
- BWEN 102.9K
- CUE 269.5K
- Earning Date
- BWEN 08-12-2025
- CUE 08-13-2025
- Dividend Yield
- BWEN N/A
- CUE N/A
- EPS Growth
- BWEN N/A
- CUE N/A
- EPS
- BWEN N/A
- CUE N/A
- Revenue
- BWEN $142,358,000.00
- CUE $7,991,000.00
- Revenue This Year
- BWEN $7.86
- CUE N/A
- Revenue Next Year
- BWEN $4.51
- CUE $23.84
- P/E Ratio
- BWEN N/A
- CUE N/A
- Revenue Growth
- BWEN N/A
- CUE 13.83
- 52 Week Low
- BWEN $1.41
- CUE $0.45
- 52 Week High
- BWEN $3.69
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- BWEN 59.28
- CUE 58.42
- Support Level
- BWEN $1.77
- CUE $0.65
- Resistance Level
- BWEN $1.95
- CUE $0.88
- Average True Range (ATR)
- BWEN 0.09
- CUE 0.07
- MACD
- BWEN -0.00
- CUE 0.02
- Stochastic Oscillator
- BWEN 65.38
- CUE 63.74
About BWEN Broadwind Inc.
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.